Rize Oncology Inc.
CNSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -34.00% | 77.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.35% | -40.79% | |||
| Operating Income | -6.35% | 40.79% | |||
| Income Before Tax | -8.14% | 41.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.14% | 41.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.14% | 41.89% | |||
| EBIT | -6.35% | 40.79% | |||
| EBITDA | -26.63% | -- | |||
| EPS Basic | -7.41% | 44.90% | |||
| Normalized Basic EPS | -5.88% | 45.16% | |||
| EPS Diluted | -7.41% | 44.90% | |||
| Normalized Diluted EPS | -5.88% | 45.16% | |||
| Average Basic Shares Outstanding | 0.44% | 6.13% | |||
| Average Diluted Shares Outstanding | 0.44% | 6.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||